


FIGURE 1




FIGURE 2



1000
900
800
700
600
500
400
300
200
100
0
Mean Tumor Volume (mm³)
0
20
40
60
80
100
Days Post Tumor Implant
Untreated
cBR96-mc-MMAF4M, 3 mg/kg
cBR96-mc-MMAF4M, 10 mg/kg
Schedule q4dx4

FIGURE 3a

Efficacy of mAb-mc-MMAF in L2987 Lung Carcinoma




Figure 3b

a




FIGURE 4a

b




FIGURE 4b

a




FIGURE 5a

b




FIGURE 5b

a




FIGURE 6a

b




FIGURE 6b



Relative Luminescence Units (RLU)
1500000
1000000
500000
0
0
0.0001
0.001
0.01
0.1
1
µg/ml
H-MC-vc-PAB-MMAF [cys] 3.8 drug/Ab
H-MC-MMAF [cys] 4.1 drug/Ab
H-MC-MMAF [cys] 4.8 drug/Ab
SK-BR-3 cells

Figure 7



RLU
2000000
1500000
1000000
500000
0
0
0.0001
0.001
0.01
0.1
1
μg/ml
H-MC-vc-PAB-MMAF [cys] 3.8 drug/Ab
H-MC-MMAF [cys] 4.1 drug/Ab
H-MC-MMAF [cys] 4.8 drug/Ab
BT-474 cells

Figure 8



RLU
2000000
1500000
1000000
500000
0
0
0.0001
0.001
0.01
0.1
1
µg/ml
MCF-7 cells
H-MC-vc-PAB-MMAF [cys] 3.8 drug/Ab
H-MC-(Me)vc-PAB-MMAF [cys] 3.9 drug/Ab
H-MC-MMAF [cys] 4.1 drug/Ab

Figure 9.



2500000
2000000
1500000
1000000
500000
RLU
MDA-MB-468 cells
H-MC-vc-PAB-MMAE [cys] 4.1 drug/Ab
H-MC-vc-PAB-MMAE [cys] 3.3 drug/Ab
H-MC-vc-PAB-MMAF [cys] 3.7 drug/Ab
0
0.0001
0.001
0.01
0.1
1
µg/ml

Figure 10



Conc (ug/mL)
100
10
1
0.1
0.01
0
4
8
12
16
20
24
28
Time (day)
H-MC-vc-PAB-MMAF-TEG Total Ab
H-MC-vc-PAB-MMAF-TEG Conj
H-MC-vc-PAB-MMAF Total Ab
H-MC-vc-PAB-MMAF Conj

Figure 11



H-MC-vc-PAB-MMAE in Cynomolgus monkeys
Concentration (ug/mL)
100
10
1
0.1
0.01
0
7
14
21
28
35
42
49
Time (day)
0.5 mg/kg, Total Antibody
0.5 mg/kg, Conjugated Antibody
3 mg/kg, Total Antibody
3 mg/kg Conjugated Antibody
1.5 mg/kg, Total Antibody
1.5 mg/kg, Conjugated Antibody
1.5 mg/kg, Total Antibody
1.5 mg/kg, Conjugated Antibody
2.5 mg/kg, Total Antibody
2.5 mg/kg, Conjugated Antibody
2.5 mg/kg, Total Antibody
2.5 mg/kg, Conjugated Antibody

Figure 12



Mean Tumor Volume (mm³)
0
100
200
300
400
500
600
700
800
0
10
20
30
40
50
Day
Vehicle
Trastuzumab-MC-vc-PAB-MMAE (1250 ug/m²)
Trastuzumab-MC-vc-PAB-MMAF (555 ug/m²)

Figure 13



Mean Tumor Volume (mm3)
200
400
600
800
1000
0
0
RX
5
10
15
Day
Vehicle
Trastuzumab-MC-MMAE
660 µg/m2
Trastuzumab-MC-vc-PAB-MMAE
1250 µg/m2

Figure 14



Mean Tumor Volume (mm3)
0
200
400
600
800
1000
RX
0
5
10
15
20
25
30
35
40
Day
Vehicle
Trastuzumab-MC-MMAF
650 µg/m 2 MMAF

Figure 15



Mean Tumor Volume (mm3)
0
100
200
300
400
500
600
700
800
0
5
10
15
20
25
30
Day
A RX
mouse sacrificed
Vehicle (Buffer)
H-MC-vc-PAB-MMAF
H-MC-vc-PAB-MMAF
H-MC-vc-PAB-MMAF
H-MC-vc-PAB-MMAF
MMAF/H
5.9
2
4
6
mg/kg Ab
4.1
12
6
4
TI
8/8
8/8
2/8
6/7
8/8
PR
0/8
2/8
2/8
4/8
3/8
CR
0/8
0/8
6/8
2/8
0/8

Figure 16



Body weight change(gms)
40.0
30.0
20.0
10.0
0.0
-10.0
-20.0
-30.0
1
2
3
4
5
Study Day
Trastuzumab-vc-MMAF
(2105 ug/m²)
Free MMAF
(2105 ug/m²)
Vehicle
Trastuzumab-vc-MMAE
(2105 ug/m²)

Figure 17



Change in Body Weight (grams)
40
30
20
10
0
-10
-20
-30
1
2
3
4
5
Study Day
Vehicle Historical Control
9.94 mg/kg H-MC-val-cit-MMAF
24.90 mg/kg H-MC-val-cit-MMAF
10.69 mg/kg H-MC(Me)-val-cit-PAB-MMAF
26.78 mg/kg H-MC(Me)-val-cit-PAB-MMAF
10.17 mg/kg H-MC-MMAF
25.50 mg/kg H-MC-MMAF
21.85 mg/kg H-MC-val-cit-PAB-MMAF

Figure 18



Change in Body Weight
Grams change from Day 1
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
-10.0
-20.0
-30.0
1
2
3
4
5
6
7
8
9
10
Study Day
Vehicle Control
2105 ug/m2 H-MC-MMAF
2105 ug/m2 H-MC-MMAF 3 wk
3158 ug/m2 H-MC-MMAF
4210 ug/m2 H-MC-MMAF

Figure 19